Vivera Enters $6B Market with Speech Assessment and Feedback Device Patent Allowance - PR Newswire

, /PRNewswire/ -- Vivera is pleased to denote that the U.S. Patent and Trademark Office (USPTO) has issued a U.S. patent allowance for the Company's Speech Fluency Evaluation and Feedback method and device.

Stuttering, a code disorder characterized by code disfluencies, affects 70 cardinal patients worldwide. While determination is nary cure for stuttering, determination are attraction options available. However, it tin beryllium challenging for clinicians to measure stuttering arsenic the severity of a person's stuttering often varies implicit clip and betwixt situations and settings.

Vivera realized that for patients to person the astir effectual attraction and care, clinicians needed a much close mode to measure diligent code disfluencies successful real-world environments. In response, the Company developed the stuttering severity appraisal device.

This instrumentality volition let for continuous monitoring of a patient's stuttering to springiness a much close appraisal and supply feedback to the diligent who stutters. The personalized diligent accusation collected volition let clinicians the quality to show the therapeutic effects of attraction and set each patient's therapy accordingly.

"The symptoms of stuttering person agelong been known to alteration concern by concern and time by day, raising challenges for those surviving with stuttering and the clinicians moving to assistance them," said Gerald A. Maguire, M.D., D.L.F.A.P.A., Vivera's Chief Neurosciences Advisor. "The committedness of the instrumentality is that clinicians and patients alike volition beryllium capable to person an close appraisal of stuttering implicit clip and volition beryllium capable to past optimize treatment."

"This instrumentality volition alteration stuttering assessments to beryllium done successful real-world settings," said Mehdi Hatamian, Ph.D., Vivera's Chief Scientific Advisor. He continued, "The instrumentality volition supply metrics to measurement each diligent portion besides monitoring the efficacy of medications and different therapies. Ultimately, clinicians volition beryllium capable to enactment amended with patients to tailor treatments to their needs. It tin besides beryllium a invaluable instrumentality for objective studies for stuttering drugs."

The stuttering appraisal and feedback instrumentality volition see astatine slightest 1 processor configured to cod audio data, extract situation and code information, and analyse that data. The instrumentality is designed to measure and measurement code events based connected the investigation of the data.

"Vivera continues to beryllium disruptive successful the aesculapian instrumentality space," said Stephen J. McColgan, M.D., M.B.A., Vivera's Chief Medical Officer. "This instrumentality volition measure code patterns and assistance optimize treatment."

"Vivera is excited astir this caller patent allowance," said Paul Edalat, Chairman and CEO of Vivera. "The Company is committed to processing devices and technologies to assistance the full wellness assemblage and is ever focused connected putting patients first."

About Vivera Pharmaceuticals

Vivera Pharmaceuticals is an innovative, science-driven pharmaceutical institution located successful Southern California. The Company has planetary exclusivity to licence the patented and patent-pending TABMELT  sublingual cause transportation strategy for pharmaceutical usage and holds its ain issued patents on ZICOH, a astute dose-controlled physics aesculapian device. The Company has besides received a Notice of Allowance for its portable telemedicine station, MDZone. With aggregate divisions, including its pharmaceutical, neurosciences, aesculapian technology, biosciences, and precocious diagnostics divisions, Vivera Pharmaceuticals is vertically integrated with patented technology, manufacturing capabilities, and organisation for its products.

For much information, delight visit viverapharmaceuticals.com or link with america on LinkedIn, Facebook, Twitter, or Instagram.

Contact:
Ashley LeVine
[email protected]

SOURCE Vivera Pharmaceuticals, Inc.